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Objective: Evidence exists for the efficacy of collaborative care (CC) for major depres-
sive disorder (MDD), for the efficacy of the consequent use of pain medication against 
pain, and for the efficacy of duloxetine against both MDD and neuropathic pain. Their 
relative effectiveness in comorbid MDD and pain has never been established so far. This 
study explores the effectiveness of CC with pain medication and duloxetine, and CC with 
pain medication and placebo, compared with duloxetine alone, on depressive and pain 
symptoms. This study was prematurely terminated because of massive reorganizations 
and reimbursement changes in mental health care in the Netherlands during the study 
period and is therefore of exploratory nature.
Methods: Three-armed, randomized, multicenter, placebo-controlled trial at three 
specialized mental health outpatient clinics with patients who screened positive for 
MDD. Interventions lasted 12 weeks. Pain medication was administered according to an 
algorithm that avoids opiate prescription as much as possible, where paracetamol, COX 
inhibitors, and pregabalin are offered as steps before opiates are considered. Patients 
who did not show up for three or more sessions were registered as non-compliant. 
Explorative, intention-to-treat and per protocol, multilevel regression analyses were per-
formed. The trial is listed in the trial registration (http://www.trialregister.nl/trialreg/admin/
rctview.asp?TC=1089; NTR number: NTR1089).
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results: Sixty patients completed the study. Patients in all treatment groups reported 
significantly less depressive and pain symptoms after 12 weeks. CC with placebo condi-
tion showed the fastest decrease in depressive symptoms compared with the duloxetine 
alone group (b = −0.78; p = 0.01). Non-compliant patients (n = 31) did not improve over 
the 12-week period, in contrast to compliant patients (n = 29). Pain outcomes did not 
differ between the three groups.
Conclusion: In MDD and pain, patient’s compliance and placebo effects are more 
important in attaining effect than choice of one of the treatments. Active pain manage-
ment with COX inhibitors and pregabalin as alternatives to tramadol or other opiates 
might provide an attractive alternative to the current WHO pain ladder as it avoids opiate 
prescription as much as possible. The generalizability is limited due to the small sample 
size. Larger studies are needed.
Keywords: collaborative care, pain, depression, duloxetine, placebo, pregabalin, algorithm
inTrODUCTiOn
Pain is common among depressive patients (1–4), with comor-
bidity rates amounting to two thirds (5). A depressive disorder 
is a risk factor for developing low-back pain (6, 7), neck pain 
(6), and joint pain (8). The burden of depression with comorbid 
pain increases the likelihood of disability to work and unemploy-
ment, decreases wellbeing (9, 10) and doubles health care costs 
compared with patients with pain without depression (10). This 
comorbidity is associated with treatment resistance and poor 
response to treatment when only the depressive symptoms are 
treated (11–13). Therefore, it is evident that treatment needs to 
address both depression and pain.
One option for a dual and integrated treatment approach that 
addresses both depression and pain is collaborative care (CC), 
which is effective in the treatment of depression (14–17) and pain 
(18). CC is a framework for multifaceted care, including psycho-
logical as well as pharmacological interventions and interdisci-
plinary collaboration of health professionals, and is applicable 
in primary, secondary, and tertiary care settings (19). In the 
Netherlands, the general practitioner (GP) acts as a gatekeeper 
for patients with mental and physical problems. In the national 
Depression Initiative, from 2006 to 2012 (20), a CC model was 
implemented and evaluated in which the GP could collaborate 
with a nurse care-manager and a consultant psychiatrist for treat-
ment of a depressive disorder in primary care (19). This model 
has proved to be successful (17, 21–23), and so was a similar 
model for anxiety disorders (24, 25) and somatoform disorders 
(26) in the primary care setting. As a result of these positive 
outcomes, and the cost-effectiveness of the model (27–30), CC 
including psychiatric consultation was taken into account in a 
rigorous reorganization cutback of mental health care provisions 
in the Netherlands (31) and was made the preferred collabora-
tion model for primary care and specialty mental health care in 
the Netherlands since 2014 by the Ministry of Health and the 
medical insurance companies. Since then, in order to cope with 
the increasing demand for mental health care in general practice, 
a policy change was introduced reimbursing the collaboration of 
GPs and mental health specialists (e.g., psychiatrists) that is now 
being implemented widely (32). Patients with mild mental health 
problems are treated in primary care (with psychopharmacologi-
cal treatment and/or short-term psychological treatment) and 
patients with moderately severe mental disorders are treated in 
basic mental health care, where no more than 12 sessions are 
offered. Patients with more complex mental health problems are 
treated in specialized mental health care. In a large randomized 
controlled trial, antidepressant treatment in combination with 
a behavioral intervention, such as problem-solving treatment 
(PST), was more effective in reducing depressive and pain 
symptoms in primary care patients (33). Antidepressants such as 
duloxetine are reported to be effective for depressive and pain 
symptoms (34–39), and appear to be more effective than SSRIs 
and placebos (36, 40). However, to co-manage pain, the use of 
analgesics might improve the effect on pain symptoms in patients 
with depression (33).
In general, the World Health Organization pain ladder is 
used in pain treatment, which suggests three steps, the second 
and third steps of which involve opiates, and antidepressants; 
pregabalin and mood stabilizers have been suggested as adjuvant 
medication (41). In the Netherlands, it is growing practice for a 
psychiatrist to prescribe pain medication. The prescribing prac-
tices for opioids, however, particularly as they relate to the man-
agement of chronic pain, have been subject to debate (42–47). It is 
advised to use non-opioid medications in the treatment of pain in 
patients with depression (44). This new development makes the 
outcomes of the present study highly relevant, as we developed a 
new algorithm that might be an attractive alternative to the WHO 
pain ladder, specifically for the comorbid condition of depressive 
disorder and pain. This algorithm lays an emphasis on avoiding 
opiates as much as possible, differentiating between nociceptive 
pain and neuropathic pain, and prescription of so-called adju-
vant medication (i.e., antidepressants and pregabalin) from the 
start instead of later or only optional in the WHO pain ladder. 
Furthermore, this new algorithm is embedded in a CC approach 
involving active monitoring of medication use and its effects. The 
algorithm is shown in Figure 1.
FigUrE 1 | Pain medication algorithm for nociceptive pain (left track), neuropathic pain (right track), and mixed pain (both tracks).
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Pain is common in patients with major depressive disorders 
(MDDs) and has a negative influence on treatment outcome. 
Furthermore, pain and depression have a bidirectional asso-
ciation: persons with pain symptoms are at increased risk for 
depression and those with depressive symptoms report more 
pain symptoms than persons without depressive symptoms (9). 
Hence, treatment should address both. Evidence exists for the 
efficacy of CC against MDD, for the efficacy of consequent use of 
pain medication against pain, and for the efficacy of duloxetine 
against both MDD and neuropathic pain. However, their rela-
tive effectiveness has not yet been established. Also, in view 
of miscellaneous results on the effectiveness of duloxetine for 
pain, a placebo condition in this specific patient group with 
comorbidity was needed. Hence, the aim of this study was to 
evaluate the effectiveness of CC with PST, pain medication and 
duloxetine, and CC with PST, pain medication and placebo, 
compared with duloxetine alone, on depressive, and pain 
outcomes. Due to several developments, the enrollment was 
severely hampered and eventually, the study was prematurely 
terminated. Surrounding the start of the study, a series of 
unprecedented changes in the organization and financial 
reimbursement of mental health care due to cutbacks were 
introduced in the Netherlands. As a result, fewer patients 
were treated in specialized mental health care. These develop-
ments in mental health care made it difficult for this study to 
complete enrollment as envisioned. This study is, therefore, of 
exploratory nature.
MaTErialS anD METHODS
Trial Design
The design of the study has been described in more detail else-
where (48) but is summarized here. This study was a three-armed, 
randomized, multicenter, and placebo-controlled trial. The three 
treatment groups of this study consisted of:
 1. CC including pain medication treatment, combined with 
duloxetine;
 2. CC, including pain medication treatment, combined with a 
placebo;
 3. duloxetine only.
The allocation of duloxetine/placebo in the CC groups was 
double-blind and the duloxetine only group was open label.
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Setting
This study was led by the Clinical Centre for Body, Mind, and 
Health, and performed within this center and two other mental 
health institutions in the Netherlands: Arkin, and GGZ inGeest. 
Inclusion took place between December 2011 and May 2014.
Ethical Statement
This study was carried out in accordance with the recommen-
dations of the scientific committees of the three participating 
institutions with written informed consent from all subjects in 
accordance with the Declaration of Helsinki. All subjects gave 
written informed consent in accordance with the Declaration of 
Helsinki. The protocol was approved by the respective scientific 
committees of the three participating institutions, the medical 
ethical committee, and by the Central Commission for Human 
Bound Research (CCMO, dossier number: NL30081.029.10). The 
trial is listed in the trial registration: http://www.trialregister.nl/
trialreg/admin/rctview.asp?TC=1089; NTR number: NTR1089.
Participants
Consecutive patients presented at three specialized mental 
health outpatient clinics were screened for MDD and pain; they 
were asked informed consent and randomly assigned to one 
of the three treatment groups. Inclusion criteria were a Patient 
Health Questionnaire depression sub-scale (PHQ9) (49) score 
of 10 or higher; an MDD classification by Mini Neuropsychiatric 
Interview (MINI interview); and a brief pain inventory (BPI) 
(50) score of 3 or higher. Exclusion criteria were: a PHQ9 lower 
than 10; a BPI score lower than 3; alcohol use of more than 3 units 
(1 unit = 1 glass of at least 0.25 l) a day; drug abuse or dependence 
in the last 6 months, defined as current use of any hard drugs 
(defined by Dutch law, e.g., XTC, cocaine, heroin, magic mush-
rooms) or cannabis; psychotic symptoms or use of antipsychotic 
medication that may influence perception of pain; use of St John’s 
wort (Hypericum Perforatum); pregnancy and breastfeeding; 
inability to participate in case of too severe language barrier; 
dementia; history of renal and liver dysfunction for which treat-
ment is needed; uncontrolled hypertension despite treatment 
for hypertension; suicidal ideation if this constitutes immediate 
danger and the need for crisis management (48). Patients were 
asked to stop their current medications, under the supervision of 
a psychiatrist, before starting with the study.
randomization
Each participating patient received a unique identification 
number. This number was inserted into a specially designed 
program for randomization. The randomization number (1 for 
CC + duloxetine, 2 for CC + placebo, and 3 for duloxetine) was 
digitally sent to the pharmacist of the VU medical center. The 
pharmacist changed the labels of medication so no information 
was provided whether the pills were duloxetine or a placebo. The 
pharmacist could identify the medication by a unique number. 
After receiving a randomization number, the pharmacist would 
send four unique medication numbers to the contact of the men-
tal health center where the patient was registered. The contact 
would ensure the psychiatrist received the correct medication for 
the included patient. Two people controlled the unique medica-
tion numbers assigned to a patient. Study investigators, research 
coordinators, attending care teams, and the patients were blinded 
to treatment allocation when randomized into one of the CC 
groups. Medication in the duloxetine alone group was open label. 
Randomization in a 1:1:1 fashion was balanced within blocks, in 
which each treatment arm would occur two times in every six 
randomizations (48, 51).
Variables
Primary Outcome: Depressive Symptoms
The severity of depressive symptoms was measured with the 
PHQ9, a brief but validated instrument that scores each of the 
DSM-IV criteria for MDD (49). Each item is scored from 0 
(not at all) to 3 (nearly every day). The total score thus varies 
from 0 to 27; higher scores indicate higher levels of depressive 
symptoms. A cut-off score of 10 or higher is recommended to 
indicate moderate levels of depression (52). Response on depres-
sive symptoms was defined as a 50% reduction of the baseline 
PHQ9 score at the end of treatment. Remission of depressive 
symptoms was defined as a score of 5 or lower on the PHQ9 at 
the end of treatment.
Secondary Outcome: Pain Symptoms
To measure pain symptoms, the item for average pain of the 
BPI (50) was used, measuring average pain severity on a scale 
of a 10-point scale (0 = no pain; 10 =  the most severe pain). 
The BPI is a self-administered questionnaire that was originally 
designed to assess cancer pain and shows good validity and 
reliability (Cronbach alpha.85) (50). The questionnaire is com-
posed of pain drawing diagrams, four items about pain intensity 
(worst pain, least pain, average pain, and pain right now), two 
items on pain relief treatment or medication, and one item on 
pain interference, with seven sub-items (general activity, mood, 
walking ability, normal walk, relations with other people, sleep, 
and enjoyment of life). The BPI was completed at every session 
(seven in total) with the psychiatrist (every other week), who 
used the BPI score to adjust the medication. Including the score 
used to screen for eligible patients and the baseline BPI score, 
a total of nine BPI measures were obtained. Response on pain 
symptoms was defined as a 50% reduction of the baseline BPI 
score at the end of treatment. Remission of pain symptoms 
was defined as a score of 2 or lower on the BPI at the end of 
treatment.
Classification of nociceptive pain, neuropathic pain, or mixed 
pain was done using the painDETECT questionnaire that was 
specifically validated for this purpose (53). The painDETECT 
classifies subjects into nociceptive, neuropathic, or ambiguous/
mixed pain based on a summative score for nine items: neu-
ropathic pain component is unlikely, nociceptive pain is more 
likely (score ≤ 12), result is ambiguous/mixed (score 13–18), and 
neuropathic pain component is likely (score ≥ 19). Seven items 
focus on sensory symptoms for pain [graded from 0 (=never) to 
5 (=strongly)], one item focuses on pain course pattern (graded 
−1 to +1), and one item focuses on pain radiation [graded 0 
(for no radiation) or +2 (for radiating pain)]. The total score of 
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the nine-item version ranges from −1 to 38. The painDETECT 
was originally developed for individuals with low-back pain and 
showed good sensitivity and specificity (53). The painDETECT 
was used in the first therapy session in the CC treatment groups 
and was used to determine the choice of pain medication accord-
ing to the pain algorithm.
Assessments
Before treatment started, all participants completed a baseline 
self-report questionnaire. During treatment, the patients 
completed self-report questionnaires BPI, PHQ9, and the 
Antidepressant Side-Effects Checklist (ASEC-21) (54) pro-
vided by the clinician every other week, according to a Case 
Registration Form (CRF). The ASEC-21 is a checklist to measure 
the number of side effects due to the use of an antidepressant. 
The CRF assessments were used for analyses.
Medications Used in the Study
In this study, duloxetine was used as an antidepressant. Patients 
started with 30  mg every day for the first 2  weeks, which was 
increased to 60 mg for the following 2 weeks. Dependent on the 
score on the PHQ9, the dose would then be raised to 90 mg (if the 
PHQ9 score was not decreased with five points) or would remain 
60 mg (if the PHQ9 score decreased by at least five points). When 
after 12  weeks no response or remission was obtained on the 
PHQ9, a switch to amitriptyline was suggested.
For pain, medication was prescribed according to the nature 
of pain, for which a distinction was made between nociceptive 
and neuropathic pain. Figure  1 shows the pain medication 
algorithm. In short, when a patient reported pain of nociceptive 
nature, paracetamol 1,000 mg 3dd was prescribed as a first step. 
When pain symptoms did not decrease in the following 2 weeks, 
etoricoxib 60 mg 1dd was added. Tramadol 50–200 mg 1dd was 
added as a third step if the severity of pain symptoms stayed the 
same after the use of etoricoxib. If the severity increased, a switch 
to the algorithm for neuropathic pain was made. For neuropathic 
pain, pregabaline was prescribed, starting with 75 mg 1dd and 
an increase of 75 mg 1dd every 2 weeks if the severity of pain 
symptoms did not decrease.
intervention
A comprehensive description of the intervention can be found 
elsewhere (48). Here, we will provide a summary of the 
intervention.
In all three treatment groups, the intervention lasted 12 weeks. 
All participants completed the painDETECT questionnaire (to 
assess nociceptive and neuropathic pain), the PHQ9, and the BPI 
at baseline. During treatment, assessments of PHQ9 and BPI were 
performed every other week. Patients who did not show up for 
three or more sessions were registered as non-compliant.
Every week, each patient had a session with a psychologist, and 
every other week a session with a psychiatrist. In case of treatment 
response (50% reduction of the initial score), but non-remission, 
as indicated by a score of >5 on the PHQ9 after 12  weeks of 
treatment, the patient was referred to the GP with subsequent 
antidepressant treatment and pain medication advice. If after 
12 weeks (after de-blinding the medication code) no treatment 
response had occurred on severity of depressive symptoms, as 
indicated as less improvement than 50% on the initial PHQ9 
score, the patient was not referred to the GP but referred instead 
for further specialized mental health care. During the treatment, 
the patient worked through a self-help manual containing infor-
mation about depression and pain symptoms, antidepressant 
medication and relaxation techniques, and was guided by the 
psychologist. The psychologist treated patients using PST, a brief, 
structured psychological intervention, consisting of seven stages 
(55). PST is based on the fact that emotional symptoms are often 
associated with problems in daily life, and it encourages patients 
to formulate practical ways of dealing with such problems (55). 
The goal of PST is to teach patients to use their own skills and 
resources to function better and, thus, improving their coping 
skills. The psychiatrist prescribed and monitored pain medica-
tion and duloxetine, and monitored possible side effects of the 
medication (48). In all treatment groups, a CRF was used to 
monitor treatment and guide the therapist to carry out treat-
ment per protocol. The psychologist and psychiatrist both had a 
CRF made for a specific patient and for their specific treatment. 
Both the CRF of the psychiatrist and of the psychologist were 
divided into sections, with each section representing a session. 
Each session started with the steps that had to be followed for 
that specific session. The CRF for the psychiatrist was as follows: 
each session started by asking about the presence and severity of 
21 common antidepressant side effects using the ASEC-21. When 
an adverse event not mentioned on the ASEC-21 was attributed 
to the antidepressant therapy, the therapist could write this down. 
Subsequently, the depressive and pain symptoms were monitored 
using the PHQ9 and the BPI. The scores on these questionnaires 
were used to determine the next step in the medication algo-
rithms, which could also be found in the current section of the 
CRF. The algorithm for pain medication is shown in Figure 1. The 
CRF for the psychologist was as follows: each session consisted of 
PST, and every session one problem was addressed that bothered 
the patient the most. These sessions took place every week.
Collaborative Care
In the CC groups, duloxetine or placebo was prescribed, and 
pain medication was administered according to an algorithm 
specifically designed for this study. This algorithm avoids opi-
ate prescription as much as possible, which is considered as an 
alternative to the current WHO pain ladder, with paracetamol, 
COX inhibitors, and pregabalin as steps before opiates are started.
In the CC groups, duloxetine (or placebo) and pain medica-
tion were administered by a psychiatrist, using an algorithm that 
is shown in Figure 1.
Collaborative care was simultaneously provided by a team of 
a care-manager (psychologist) and a psychiatrist. Only patients 
in the CC groups were treated by all specialists. The care- 
manager was responsible for PST, a brief, structured psychologi-
cal intervention.
Duloxetine Only
The patients in the duloxetine only group received treatment of 
the psychiatrist who used a CRF and the duloxetine algorithm in 
prescribing duloxetine.
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Compliance
Patients had to show up at least 80% of the sessions to be consid-
ered as compliant to treatment. Patients who did not show up for 
three or more sessions (20% of the sessions) were registered as 
non-compliant (48).
Statistical Methods
Due to the premature termination of this study, not all data 
could be used for analyses, and the follow-up period of 12 weeks 
was used instead of the planned 12 months. However, based on 
several studies that were performed after the initial planning of 
our study, in which we assumed 189 patients would be needed 
to enable us to find a result, we recalculated the power (56) of 
the study to estimate if analysis of the CRF data might be useful. 
We found three relevant studies. A study reporting treatment 
response on the PHQ9 comparing duloxetine with placebo 
(57) found 66% response in duloxetine versus 25% in placebo; 
to find a similar effect, assuming alpha 0.05 and power 80%, 
the n should be 24 patients for each treatment arm. Two other 
trials, one comparing duloxetine to placebo (35), and an RCT 
comparing CC versus care as usual (17) found similar differences 
in effect. Hence, as we had 20 patients per arm, we decided to 
evaluate a preliminary estimate of efficacy of CC and duloxetine 
with pain medication as intended previously, with the data from 
the CRF assessments, as it might be possible to find an effect. 
Nevertheless, these should be considered exploratory analyses 
rather than hypothesis testing. A full report on the factors that 
hampered this study and led to the premature termination of 
this study can be requested from the corresponding author. 
The 12 weeks CRF assessments were available only for limited 
analyses. Although the sample size was smaller than intended, 
explorative, intention-to-treat and per protocol, multilevel 
regression analyses (MLAs) were performed.
Descriptive analyses were performed to describe the sample 
at baseline, regarding gender, age, compliance, severity of depres-
sive symptoms, and pain severity. Differences between treatment 
groups and between compliant and non-compliant patients 
were analyzed regarding baseline characteristics. All linear vari-
ables were normally distributed (normality was tested with the 
Shapiro–Wilk test). Although the required sample sizes were not 
reached, we performed explorative, intention-to-treat, MLAs. We 
evaluated the effect of time for the whole sample, the effect of the 
treatment group, and the effect of the treatment group over time 
in terms of depressive symptoms and in terms of pain symptoms 
over a 16-week period (from moment of screening to the end of 
the therapy sessions). Quadratic functions of time were included 
to examine whether there was an initial increase in outcomes fol-
lowed by a decrease (negative quadratic function), or the other 
way around (positive quadratic function). Third, explorative, per-
protocol MLAs were used to evaluate the effect in case of compli-
ance. Data from all 60 participants were used in the analyses. 
In the per-protocol analyses, the compliant and non-compliant 
patients were separately analyzed to examine differences between 
these groups. There were no dropouts. The duloxetine only 
group was used as the reference group in all analyses because we 
expected the CC groups to be the most effective compared with 
the duloxetine only group. The number of side effects that were 
reported on the ASEC-21 is presented for the total sample and 
for all the treatment groups. Between group analyses (one-way 
ANOVA, with LSD post  hoc test) were performed to examine 
whether the number of side effects reported would differ between 
the treatment groups.
rESUlTS
Participant Flow
The inclusion and follow-up of patients is shown in the flowchart 
in Figure  2. Of the 76 eligible patients, 16 were excluded for 
several reasons, including having an elevated risk of suicide or not 
being fluent in Dutch. Twenty-one patients (35%) were randomly 
assigned to the CC with duloxetine condition, 20 patients (33.3%) 
to the CC with placebo condition, and 19 patients (31.7%) to 
the duloxetine alone condition. Of the total sample, 29 patients 
(48.3%) were compliant, whereas 31 patients (51.7%) were non-
compliant for several reasons: (a) side effects; (b) did not want 
the medication; (c) did not want to continue in the study; (d) 
moved to another city; and (e) needed/wanted other care. Of all 
included patients, follow-up measurements were attained during 
the intervention period, hence no loss of follow-up occurred in 
this time frame.
Baseline Characteristics
Table 1 shows the baseline characteristics of the total sample and 
the three treatment groups. The total sample consisted of more 
women than men, with a mean age of 43. Mean score of the PHQ9 
was 17.45 and of the BPI 6.92. Most patients reported neuropathic 
pain (n = 20), and only five patients reported pain of both a noci-
ceptive and neuropathic nature. No significant differences were 
found between the three treatment groups regarding gender, age, 
depressive symptoms, and pain symptoms. The two CC groups did 
not differ regarding the nature of pain. Table 2 shows the baseline 
characteristics of compliant and non-compliant patients. Both 
groups consisted of more women than men. Mean age was 41.9 
and 44.4 for compliant and non-compliant, respectively. Mean 
PHQ9 score was somewhat higher for non-compliant patients 
(mean = 17.9) than for compliant patients (mean = 17.0), and mean 
score of the BPI was higher for compliant patients (mean = 7.2) 
than for non-compliant patients (mean =  6.7). In both groups, 
an equal number of patients reported pain of nociceptive nature 
(n = 7) and of neuropathic nature (n = 10). No significant dif-
ferences were found between compliant versus non-compliant 
patients regarding gender, age, treatment condition, severity of 
depressive and pain symptoms, and nature of pain.
intention-to-Treat analysis
As is shown in Table 3, patients in all treatment groups reported 
significant lower depressive (b = −0.34; p = < 0.001) and pain 
(b = −0.07; p =  0.01) symptoms after therapy (Table  3). ITT 
analysis showed that, for pain, both CC treatment groups did not 
show significantly better results than the duloxetine alone group. 
For the outcome of depression, the CC with placebo condition 
showed the fastest decrease compared with the duloxetine alone 
group (b = −0.78; p = 0.01), but this effect diminished at the end 
TaBlE 1 | Gender, age and mean of pain, and depressive symptoms at baseline of the total sample and three treatment conditions.
Total sample, N = 60 CC + duloxetine, n = 21 (35%) CC + placebo, n = 20 (33.3%) Duloxetine, n = 19 (31.7%)
Sample characteristics
Female gender, n (%) 36 (60%) 15 (71.4) 10 (50) 11 (57.9)
Age, mean (SD) 43.2 (12.4) 41.9 (12.2) 41 (12.9) 46.9 (11.7)
PHQ9, mean (SD) 17.5 (4.3) 17.2 (4.2) 17.5 (5.0) 17.7 (3.7)
BPI, mean (SD) 6.9 (1.7) 6.7 (2.1) 7.1 (1.4) 7.0 (1.5)
nature of pain, n(%)a
Nociceptive
Neuropathic
Mixed
14 (23.3%)
20 (33.3%)
5 (8.3%)
7 (33.3%)
10 (47.6%)
3 (14.3%)
7 (35%)
10 (50%)
2 (10%)
aPatients in the duloxetine alone group (n = 19) did not receive pain medication, therefore, no information was obtained on nature of pain for those patients. Of two other patients, 
information regarding nature of pain was missing.
FigUrE 2 | Overview of inclusion, divided in three research groups and number of non-compliant (having missed three or more sessions) and compliant patients.
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of treatment (Figure 3). Figures 3 and 4 show the mean PHQ9 
and mean BPI scores of the three treatment groups over time, 
respectively.
Per-Protocol analysis
Per-protocol analysis with the compliant patients showed com-
parable results as the ITT analysis (Table  4). Non-compliant 
patients did not improve over the 12-week period for depressive 
or pain symptoms (results not shown).
adverse Effects
Table  5 shows the number of patients who reported adverse 
effects, measured with the ASEC-21. Most patients experienced 
drowsiness, a dry mouth, nausea, feeling light-headed, insom-
nia, headache, and sweating. In the placebo condition, adverse 
effects were also experienced. In this treatment condition, most 
patients experienced insomnia, drowsiness, feeling light-headed, 
a dry mouth, and sweating. In the duloxetine alone condition, 
headache was the most reported adverse effect. Adverse effects 
reported by patients in the CC with duloxetine treatment group 
are due to both duloxetine and the pain medication. Adverse 
effects reported by patients in the CC with placebo treatment 
group are most likely due to only the pain medication. In the 
duloxetine alone treatment group, the reported adverse effects 
are due to duloxetine. Patients in the CC + duloxetine treatment 
group reported significantly more side effects than patients in the 
other treatment groups (F =  6.27; p = <  0.01). No significant 
differences were found between the duloxetine alone treatment 
group and the CC + placebo treatment group.
DiSCUSSiOn
We carried out a randomized controlled trial, testing and 
comparing the effectiveness of three active treatments among 
TaBlE 3 | Intention-to-treat, multilevel analyses comparing the CC + duloxetine and CC + placebo treatment groups with the duloxetine alone treatment group for 
depressive and pain symptoms.
Total sample, N = 60 CC + duloxetine, n = 21 CC + placebo, n = 20 Duloxetine, n = 19
β (95% Ci) β (95% Ci) β (95% Ci)
Depression
Effect of time −0.34 (−0.47 to −0.20)a Reference
Effect of treatment group −0.31 (−3.16 to 2.54) −0.54 (−3.43 to 2.34) Reference
Effect of treatment group and time −0.28 (−0.83 to 0.27) −0.78 (−1.33 to −0.22)a Reference
Effect of treatment group and time (quadratic) 0.02 (−0.01 to 0.05) 0.04 (0.01 to 0.07)ap = 0.01 Reference
Pain
Effect of time −0.07 (−0.13 to −0.02)a Reference
Effect of treatment group −0.27 (−1.24 to 0.71) 0.26 (−0.73 to 1.24) Reference
Effect of treatment group and time 0.15 (−0.09 to 0.40) −0.13 (−0.39 to 0.12) Reference
Effect of treatment group and time (quadratic) −0.01 (−0.02 to 0.01) 0.01 (−0.01 to 0.02) Reference
aSignificant at the 0.05 level; CC, collaborative care; time, time from screening to end of therapy sessions; significant results are bold.
TaBlE 2 | Gender, age, treatment condition, depressive and pain symptoms, 
and nature of pain at baseline of compliant (n = 29) and non-compliant (n = 31) 
patients.
Compliant patients 
(n = 29)
non-compliant patients 
(n = 31)
Sample characteristics
Female gender, n (%) 16 (55.2) 20 (64.5)
Age, mean (SD) 41.9 (11.4) 44.4 (13.4)
Treatment condition, n (%)
CC + duloxetine
CC + placebo
Duloxetine
10 (34.5%)
10 (34.5%)
9 (31.0%)
11 (35.5%)
10 (32.3%)
10 (32.3%)
PHQ9, mean (SD) 17.0 (4.0) 17.9 (4.6)
BPI, mean (SD) 7.2 (1.6) 6.7 (1.7)
nature of pain, n(%)a
Nociceptive
Neuropathic
Mixed
7 (24.1%)
10 (34.5%)
3 (10.3%)
7 (22.6%)
10 (32.3%)
2 (6.5%)
aPatients in the duloxetine alone group (n = 19) did not receive pain medication, 
therefore, no information was obtained on nature of pain for those patients. Of two 
other patients, information regarding nature of pain was missing.
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patients with moderately severe MDD and comorbid pain. This 
is a notoriously hard group of patients to engage and treat, and the 
prognosis of both dimensions of symptoms, when left untreated, is 
unlikely to be favorable (11–13). Our first result is that, at the end 
of the treatment, patients in all treatment groups had significantly 
less pain and depressive symptoms. Considering pain, there were 
no significant differences between the three treatments. However, 
the depressive symptoms decreased faster among patients in the 
CC with placebo group than among patients in the duloxetine 
only group. For patients who were non-compliant, depressive, 
and pain symptoms did not decrease, which indicates that the 
treatments provided did play a role in the outcomes. Hence, our 
findings suggest that in comorbid MDD and pain, compliance of 
the patient and placebo effects are more crucial than choice of one 
of the three treatments explored in this RCT.
A review of 79 studies comparing CC with routine care or 
alternate treatments found that CC leads to greater improvement 
than care as usual in depression outcomes in the short term as 
well as the long term (14). Our results also show a significant 
improvement of depressive symptoms when CC is offered. The 
effect occurs faster in the CC + placebo arm. However, at the end 
of the intervention period, the outcome is similar in the three 
treatment arms. In our study, duloxetine had no surplus value for 
patients in the CC groups, both for depressive symptoms and for 
pain, which was against our expectations based on studies exam-
ining the effect of duloxetine on depression and pain (34, 36, 40). 
Our findings do correspond with a meta-analysis of duloxetine’s 
purported analgesic effects on depressed patients, in which the 
analgesic effects of duloxetine were not supported (58).
The finding that the CC with placebo condition seems to be 
the most optimal condition in this study is intriguing. A possible 
explanation might be the placebo effect, which could increase 
the effect of CC, at least at the beginning of therapy. Patients in 
both CC groups most likely have an expectation of a reward (i.e., 
expectation of less pain and depressive symptoms) and had expe-
rience with the use of similar medications, have learned the (posi-
tive) effects of these medications, and are therefore more likely to 
experience a positive effect (classical conditioning), which might 
contribute to less psychological and physical symptoms (59, 60). 
Considering that side effects of an antidepressant tend to occur 
mostly in the first few weeks of use might be a possible explana-
tion as experiencing side effects can increase the likelihood of a 
poorer treatment outcome (61). Hence, we examined the occur-
rence of side effects in the three treatment groups. As described 
in the results, no significant differences in terms of side effects 
were found between the duloxetine alone and the CC + placebo 
treatment groups, but treatment response was fastest in the 
CC + placebo treatment group. Patients in the CC + duloxetine 
treatment group, however, reported significantly more side effects 
than patients in the other two treatment groups. This suggests that 
the fast treatment response in the CC + placebo treatment group 
has to do with receiving a high level of care and attention (CC) 
and with experiencing less side effects (placebo). We would like 
to encourage similar studies among larger sample sizes and longer 
follow-up periods to explore the possible mechanism further and 
to enhance the generalizability of our results.
This study is a first step to establish an effective treatment for 
the combination of depression and pain. A major strength of 
FigUrE 3 | Mean Patient Health Questionnaire 9 (PHQ9) score of the three treatment groups over time.
FigUrE 4 | Mean brief pain inventory (BPI) score of the three treatment groups over time.
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this study is the use of an algorithm for pain medication, which 
distinguishes nociceptive pain from neuropathic pain. A WHO 
pain ladder algorithm does exist, but that algorithm focuses 
mainly on nociceptive pain. An algorithm for neuropathic 
pain was not yet available. The results indicate that active 
pain management in CC with COX inhibitors and pregabalin 
as alternatives to tramadol or other opiates might provide an 
attractive alternative to the current WHO pain ladder as it 
TaBlE 5 | Number of patients who reported side effects of duloxetine/placebo measured with the ASEC-21.
Symptom Total sample (N = 60), n(%) CC + duloxetine (n = 21), n(%) CC + placebo (n = 20), n(%) Duloxetine (n = 19), n(%)
Drowsiness 28 (47) 11 (52) 8 (40) 9 (47)
Dry mouth 27 (45) 12 (57) 7 (35) 8 (42)
Nausea or vomiting 27 (45) 13 (62) 5 (25) 9 (47)
Feeling light-headed on standing 27 (45) 13 (62) 8 (40) 6 (32)
Insomnia 26 (43) 11 (52) 9 (45) 6 (32)
Headache 25 (42) 9 (43) 6 (30) 10 (53)
Sweating 23 (38) 7 (33) 7 (35) 9 (47)
Yawning 18 (30) 8 (38) 3 (15) 7 (37)
Decreased appetite 17 (28) 7 (33) 5 (25) 5 (26)
Tremor 15 (25) 7 (33) 5 (25) 3 (16)
Blurred vision 14 (23) 7 (33) 4 (20) 3 (16)
Feeling like the room is spinning 13 (22) 8 (38) 4 (20) 1 (5)
Weight gain 13 (22) 7 (33) 3 (15) 3 (16)
Constipation 12 (20) 5 (24) 2 (10) 5 (26)
Problems with sexual function 10 (17) 6 (29) 0 (0) 4 (21)
Diarrhea 9 (15) 3 (14) 5 (25) 1 (5)
Increased appetite 9 (15) 5 (24) 1 (5) 3 (16)
Palpitations 9 (15) 6 (29) 1 (5) 2 (11)
Disorientation 8 (13) 5 (24) 1 (5) 2 (11)
Problems with urination 7 (12) 3 (14) 1 (5) 3 (16)
Increased body temperature 3 (5) 0 (0) 3 (15) 0 (0)
Average number of side effects 16 7.3a 4.2 4.7
Adverse effects reported by patients in the collaborative care with duloxetine treatment group are due to both duloxetine and the pain medication. Adverse effects reported by 
patients in the collaborative care with placebo treatment group are most likely due to only the pain medication. In the duloxetine alone treatment group, the reported adverse effects 
are due to duloxetine.
aSignificantly different at 0.05 level, using one-way ANOVA with LSD post hoc test, compared with CC + placebo and compared with duloxetine only.
TaBlE 4 | Explorative, per protocol, multilevel analyses comparing the CC + duloxetine, and CC + placebo treatment groups with the duloxetine alone treatment group 
for depressive and pain symptoms for patients who were compliant.
Total sample, N = 60 CC + duloxetine, n = 21 CC + placebo, n = 20 Duloxetine, n = 19
β (95% Ci) β (95% Ci) β (95% Ci)
Depression
Effect of time −0.37 (−0.53 to −0.22)a Reference
Effect of treatment group −0.52 (−4.58 to 3.54) 0.19 (−3.83 to 4.22) Reference
Effect of treatment group and time −0.17 (−0.86 to 0.52) −0.72 (−1.40 to −0.04)a Reference
Effect of treatment group and time (quadratic) 0.02 (−0.02 to 0.05) 0.04 (0.01 to 0.07)a Reference
Pain
Effect of time −0.13 (−0.20 to −0.06)a Reference
Effect of treatment group −0.77 (−2.17 to 0.64) 0.11 (−1.27 to 1.49) Reference
Effect of treatment group and time 0.20 (−0.14 to 0.54) −0.15 (−0.48 to 0.18) Reference
Effect of treatment group and time (quadratic) −0.01 (−0.02 to 0.01) 0.01 (−0.01 to 0.03) Reference
aSignificant at the 0.05 level; CC, collaborative care; time, time from screening to end of therapy sessions; significant results are bold.
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avoids opiate prescription as much as possible. Recently, it was 
suggested that adaptations of the original WHO pain ladder are 
needed (62). For example, opioids should be considered as adju-
vant medications instead of the principal medication for the 
treatment of pain (62), and in other research, it is discussed to 
select medication for patients with neuropathic pain with good 
therapeutic effects and a small likelihood of side effects, such as 
pregabalin (63). Our algorithm is, therefore, a next step in the 
adaptation of the existing pain ladder and might be useful for 
health professionals around the world who treat patients with 
pain symptoms. Another strength is the use of a placebo condi-
tion in combination with a three-armed design that enabled us 
to explore the relative effect of CC, pain medication algorithm, 
and duloxetine alone.
This study has several limitations that need to be addressed, 
however. All treatment groups had some form of active treatment, 
which makes spontaneous recovery or the natural fluctuation of 
symptoms hard to address. However, in a large observational 
study, severity of pain did not change over time, and even 
increased in those persons with depressive symptoms when 
compared with healthy persons (64), so the decrease in depressive 
and pain symptoms as found in this study might be accounted for 
by the treatment offered. Also, the fact that patients in our study 
who did not comply with the treatment did not improve is an 
indication that improvement of depressive and pain symptoms 
was associated with treatment. In this study, we examined the 
effectiveness of CC, in which we included a new pain management 
program. We could, however, not assess the impact of this pain 
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management program on treatment effect separately. Therefore, 
a need exists for future studies also including a treatment group 
consisting of CC including duloxetine, but no pain management 
program, to examine whether a pain management program 
increases treatment effect on top of CC and duloxetine. This also 
applies to the effect of CC alone. To measure the effectiveness of 
CC, future research needs to include a treatment group consisting 
of only CC. As mentioned before, the sample size of this study is 
small due to the reasons described. Although significant results 
were found, these need to be interpreted with some caution. 
Research with a larger sample size is needed for generalizability 
of the results. This study used a follow-up period of 12 weeks, 
so no inferences could be made regarding the long-term effect 
of these treatments after end of treatment. However, in a review 
comparing CC with other treatments, CC had a significant effect 
on depression outcomes for up to two years after treatment (14), 
and it is, therefore, plausible that the therapeutic effects found 
in this study might also last for a longer period than used in this 
study. To study long-term effects and the cost-effectiveness of 
these treatments, which was envisioned in the original design, 
both a larger sample size and longer follow-up period are needed. 
Moreover, to effectively conduct such a study, if possible, future 
health policies of government and health insurance companies 
should be taken into account, as these can influence the feasibility 
of the study greatly. Including more mental health organizations 
might also decrease the inclusion period and increase the number 
of inclusions, which might add to a successful completion of the 
study. Starting with a feasibility study can help in successfully 
conducting a full-scale randomized controlled trial for CC for 
pain and depression in the Netherlands.
The findings from this study are better thought of as hypothesis 
forming rather than hypothesis testing, and it would be necessary 
to see the conclusions replicated in future trials. However, CC 
with active pain management seems promising in the treatment 
of depression when pain is present and our pain medication algo-
rithm might provide an attractive alternative to the current WHO 
pain ladder. This needs further exploration in full-scale trials.
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